Manufacturing

Considering Blow-Fill-Seal for Biologic Drugs

The continuous, aseptic fill/finish process is finding use in vaccines and biologic drugs.

The Lighthouse Effect

Lighthouse manufacturing techniques utilize technology and automation to streamline production.

Qualifying AI Algorithms in Pharma Manufacturing

Qualified algorithms enable validation of machine learning models.

Driving Efficiencies in DSP Separation and Purification

May 03, 2022

An increasingly complex development pipeline and industry considerations, such as sustainability, are leading to a greater need for more efficient separation and purification in downstream processing.

Emerging Therapies Face Development Hurdles

May 02, 2022

Complex hurdles complicate the development of emerging therapies.

Emerging Plant-based Platform for Biomanufacturing

May 02, 2022

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

Addressing the Training Gap for Single-Use Technologies

May 02, 2022

Workforce training is crucial for biopharmaceutical manufacturing.

Addressing Limitations of Sterility Testing

May 01, 2022

Understanding both the challenges and solutions of aseptic manufacturing.

Perspectives on Process Analytical Technology

May 01, 2022

This article summarizes industry views on PAT in bioprocess-related applications and presents a vision for the biopharmaceutical industry to achieve Industry 4.0.

Using a Modeling Approach to Preclinical Studies

May 01, 2022

Applying modeling methods in preclinical studies can be a powerful tool for generating data and shortening development timelines.

Societal CDMO Awarded Manufacturing and Packaging Task by National Cancer Institute

April 28, 2022

Societal CDMO has been awarded a new manufacturing and packaging task order agreement by National Cancer Institute.

FDA Approves Kite’s CAR T-Cell Therapy Manufacturing Facility in Maryland

April 22, 2022

FDA has approved commercial production at Kite’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

Catalent to Invest $350 Million in Manufacturing Facility in Bloomington, Indiana

April 22, 2022

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.